PCH
CYTK icon

Polar Capital Holdings’s Cytokinetics CYTK Stock Holding History

Polar Capital Holdings’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$192M Buy
2,253,649
+592,401
+36% +$42.5M 0.45% 52
2026
Q1 		$109M Sell
1,661,248
-761,364
-31% -$48.4M 0.39% 61
2025
Q4 		$154M Sell
2,422,612
-360,318
-13% -$22.4M 0.59% 50
2025
Q3 		$153M Sell
2,782,930
-15,471
-0.6% -$637K 0.74% 39
2025
Q2 		$92.5M Buy
2,798,401
+342,664
+14% +$11.9M 0.48% 56
2025
Q1 		$98.7M Buy
2,455,737
+259,016
+12% +$11.9M 0.6% 47
2024
Q4 		$103M Sell
2,196,721
-141,126
-6% -$7.33M 0.58% 49
2024
Q3 		$123M Sell
2,337,847
-116,818
-5% -$6.51M 0.59% 38
2024
Q2 		$133M Buy
2,454,665
+849,089
+53% +$51.3M 0.78% 33
2024
Q1 		$113M Buy
1,605,576
+188,522
+13% +$14.6M 0.59% 41
2023
Q4 		$118M Sell
1,417,054
-1,237,391
-47% -$44.8M 0.72% 32
2023
Q3 		$78.2M Hold
2,654,445
– – 0.58% 50
2023
Q2 		$86.6M Buy
2,654,445
+42,753
+2% +$1.58M 0.44% 54
2023
Q1 		$91.9M Sell
2,611,692
-113,085
-4% -$4.61M 0.6% 45
2022
Q4 		$125M Buy
2,724,777
+53,129
+2% +$2.29M 1% 21
2022
Q3 		$129M Sell
2,671,648
-355,000
-12% -$17.1M 0.82% 20
2022
Q2 		$119M Sell
3,026,648
-154,652
-5% -$6.23M 0.7% 26
2022
Q1 		$117M Sell
3,181,300
-490,669
-13% -$17.4M 0.53% 36
2021
Q4 		$167M Buy
3,671,969
+657,087
+22% +$25.4M 0.63% 30
2021
Q3 		$108M Buy
3,014,882
+585,782
+24% +$17.2M 0.44% 45
2021
Q2 		$48.1M Sell
2,429,100
-242,784
-9% -$5.7M 0.21% 105
2021
Q1 		$62.1M Sell
2,671,884
-600,000
-18% -$12.8M 0.38% 76
2020
Q4 		$68M Buy
+3,271,884
New +$59.8M 0.41% 70

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Polar Capital Holdings's CYTK Position: Q2 2026 in Review

Polar Capital Holdings increased its Cytokinetics (CYTK) stake by 36% in Q2 2026, buying an estimated $42.5M and bringing the position to 2,253,649 shares worth $192M. The position accounts for 0.45% of the portfolio, ranked #52.

Polar Capital Holdings first reported a position in CYTK in Q4 2020 and has held it in 23 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Polar Capital Holdings held 2,253,649 shares of Cytokinetics worth $192M as of Q2 2026.
  • Polar Capital Holdings bought 592,401 Cytokinetics shares in Q2 2026, an estimated $42.5M.
  • Cytokinetics made up 0.45% of Polar Capital Holdings's portfolio in Q2 2026, its #52 holding.
  • Polar Capital Holdings first reported a position in Cytokinetics in Q4 2020 and has held it in 23 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Polar Capital Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.